Nemocnice AGEL Novy Jicin a.s.

At Nemocnice AGEL Novy Jicin a.s., investigators are advancing therapies for immune system diseases such as atopic dermatitis and related eczema, testing novel biologic agents to improve skin health and patient quality of life.

• Atopic Dermatitis
• Atopic Hand Eczema
• Moderate-to-severe Atopic Dermatitis

These studies evaluate safety and long‑term effectiveness of subcutaneous biologics compared with placebo, offering participants early access to potentially disease‑modifying treatments.

The oncology program at Nemocnice AGEL Novy Jicin a.s. addresses a range of neoplasms, including kidney, prostate, endometrial, lung and ovarian cancers, by testing new immunotherapy combinations and targeted drugs aimed at extending survival.

• Advanced Clear Cell Renal Cell Carcinoma
• High‑Risk Localized Prostate Cancer
• Metastatic Castration‑Resistant Prostate Cancer
• Advanced or Recurrent Endometrial Cancer
• c‑Met Overexpressing Non‑Squamous NSCLC
• Platinum‑Sensitive Epithelial Ovarian Cancer
• Renal Cell Carcinoma Post‑Nephrectomy

Primary goals include measuring progression‑free and overall survival, providing patients with innovative options beyond standard care.

Research in skin and connective tissue diseases focuses on chronic conditions like atopic dermatitis and severe hand eczema, exploring next‑generation monoclonal antibodies to reduce disease activity.

• Atopic Dermatitis
• Atopic Hand Eczema
• Severe Atopic Dermatitis

Trials use validated severity indices to compare investigational agents with placebo, seeking to broaden therapeutic choices for individuals with persistent skin inflammation.